NASDAQ · Drug Manufacturers - Specialty & Generic · USD
PRF Technologies Ltd. (PRFX) Stock Analysis
PRF Technologies Ltd. (PRFX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
PRFX Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.76
- Previous Close
- $0.72
- Day's Range
- 0.75–0.78
- 52-Week Range
- 0.69–7.95
- Volume
- 18.11K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.08
Valuation
- Market Cap
- $2.67M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 86.24
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.09
Financials (FY)
- Revenue (FY)
- $17.00K
- Net Income (FY)
- −$5.02M
- Shares Outstanding
- 3.50M
- 1-Year Return
- −88.06%
Dividend and dates
- Avg Volume
- 284.43K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, PRFX closed at $0.76, −88.06% over 1 year.
PRF Technologies Ltd. (PRFX) has a market capitalization of $2.67M.
In fiscal 2025, PRFX reported revenue of $17.00K.
PRFX Stock Return by Calendar Year
PRF Technologies Ltd. (PRFX) return since Sep 2020: what $10,000 became
- 1 year
- $10,000 $1,194
- −88.06%
- 5 years
- $10,000 $10
- −99.90%
- Since Sep 2020
- $10,000 $4
- −99.96%
If you had invested $10,000 in PRF Technologies Ltd. (PRFX) at the close on September 1, 2020, the earliest close on record here, it would have been worth $4 at the close on October 21, 2026: −99.96% in total, −72.32% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −76.20% |
| 2025 | −80.86% |
| 2024 | −79.67% |
| 2023 | −33.41% |
| 2022 | −68.95% |
| 2021 | −70.25% |
| 2020 (partial year) | −33.68% |
As of October 21, 2026.
PRFX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $17.00K | −$5.02M | −29,541.2% |
| 2024 | $0.00 | −$14.59M | — |
| 2023 | $0.00 | −$9.34M | — |
| 2022 | $0.00 | −$8.79M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $17.00K | −$53.00K | −$5.12M | −$5.02M | −29,541.2% |
| 2024 | $0.00 | $0.00 | −$14.67M | −$14.59M | — |
| 2023 | $0.00 | $0.00 | −$9.58M | −$9.34M | — |
| 2022 | $0.00 | — | −$8.87M | −$8.79M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
PRFX Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 97 stocks| Metric | PRFX | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/S ratio | 86.24 | 2.10 | 41.1x the median |
Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
YahooPRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform
YahooPRF Technologies Intends To Establish GridFeed Subsidiary
BenzingaPRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business
YahooPRF Technologies Issues Shareholder Letter Regarding Stronger Financial Position, Diversified Portfolio Of Innovative Technology Businesses, Real Commercial Momentum And Increased Strategic Flexibility
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B